IL250905B - Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer - Google Patents
Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancerInfo
- Publication number
- IL250905B IL250905B IL250905A IL25090517A IL250905B IL 250905 B IL250905 B IL 250905B IL 250905 A IL250905 A IL 250905A IL 25090517 A IL25090517 A IL 25090517A IL 250905 B IL250905 B IL 250905B
- Authority
- IL
- Israel
- Prior art keywords
- predictive
- colon cancer
- biomarkers associated
- angiogenic therapy
- metastatic colon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051091P | 2014-09-16 | 2014-09-16 | |
| US201562099630P | 2015-01-05 | 2015-01-05 | |
| PCT/US2015/049279 WO2016044041A1 (en) | 2014-09-16 | 2015-09-10 | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL250905A0 IL250905A0 (en) | 2017-04-30 |
| IL250905B true IL250905B (en) | 2019-12-31 |
Family
ID=54207741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL250905A IL250905B (en) | 2014-09-16 | 2017-03-02 | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10525104B2 (https=) |
| EP (1) | EP3194974B1 (https=) |
| JP (1) | JP6692358B2 (https=) |
| KR (1) | KR102471057B1 (https=) |
| CN (1) | CN107076749B (https=) |
| AU (1) | AU2015318207B2 (https=) |
| CA (1) | CA2960890A1 (https=) |
| EA (1) | EA036671B1 (https=) |
| IL (1) | IL250905B (https=) |
| MX (1) | MX382673B (https=) |
| WO (1) | WO2016044041A1 (https=) |
| ZA (1) | ZA201701664B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3734609A1 (en) | 2013-03-14 | 2020-11-04 | Otraces Inc. | A method for improving disease diagnosis using measured analytes |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| RU2021137343A (ru) | 2016-01-22 | 2022-01-26 | Отрэйсис, Инк. | Системы и способы улучшения диагностики заболеваний |
| US12019068B2 (en) | 2017-03-31 | 2024-06-25 | Hirotsu Bio Science Inc. | Method for predicting therapeutic effect and/or recurrence monitoring in cancer patients |
| AU2019212622B2 (en) | 2018-01-26 | 2024-05-23 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| WO2020165483A1 (es) * | 2019-02-15 | 2020-08-20 | Universidad de Córdoba | Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos |
| WO2021011491A1 (en) * | 2019-07-13 | 2021-01-21 | Otraces Inc. | Improving diagnosis for various diseases using tumor microenvironment active proteins |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20220390456A1 (en) * | 2019-10-17 | 2022-12-08 | Board Of Regents, The University Of Texas System | Small extracellular vesicle-associated vegf as a predictor for therapeutic responses |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| CN101283280A (zh) * | 2005-08-18 | 2008-10-08 | Zadec私人有限公司 | 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途 |
| EP2464366A2 (en) * | 2009-08-14 | 2012-06-20 | Allergan, Inc. | Methods of treating cancer using growth factor retargeted endopeptidases |
| KR101523419B1 (ko) * | 2010-01-19 | 2015-05-27 | 에프. 호프만-라 로슈 아게 | 베바시주맙 병용 치료법을 위한 종양 조직 기본 바이오마커 |
| CA2805618A1 (en) | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
-
2015
- 2015-09-10 MX MX2017003387A patent/MX382673B/es unknown
- 2015-09-10 JP JP2017533704A patent/JP6692358B2/ja active Active
- 2015-09-10 EA EA201790549A patent/EA036671B1/ru unknown
- 2015-09-10 WO PCT/US2015/049279 patent/WO2016044041A1/en not_active Ceased
- 2015-09-10 AU AU2015318207A patent/AU2015318207B2/en active Active
- 2015-09-10 CN CN201580049558.1A patent/CN107076749B/zh active Active
- 2015-09-10 EP EP15771819.8A patent/EP3194974B1/en active Active
- 2015-09-10 KR KR1020177007326A patent/KR102471057B1/ko active Active
- 2015-09-10 CA CA2960890A patent/CA2960890A1/en active Pending
- 2015-09-10 US US15/509,461 patent/US10525104B2/en active Active
-
2017
- 2017-03-02 IL IL250905A patent/IL250905B/en active IP Right Grant
- 2017-03-08 ZA ZA2017/01664A patent/ZA201701664B/en unknown
-
2019
- 2019-11-21 US US16/690,459 patent/US11439683B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA201790549A1 (ru) | 2017-07-31 |
| JP6692358B2 (ja) | 2020-05-13 |
| MX2017003387A (es) | 2018-01-30 |
| ZA201701664B (en) | 2018-05-30 |
| AU2015318207A1 (en) | 2017-04-06 |
| AU2015318207B2 (en) | 2021-11-04 |
| EA036671B1 (ru) | 2020-12-07 |
| EP3194974B1 (en) | 2019-10-23 |
| US11439683B2 (en) | 2022-09-13 |
| IL250905A0 (en) | 2017-04-30 |
| CA2960890A1 (en) | 2016-03-24 |
| WO2016044041A1 (en) | 2016-03-24 |
| US20200129589A1 (en) | 2020-04-30 |
| CN107076749A (zh) | 2017-08-18 |
| JP2017530372A (ja) | 2017-10-12 |
| MX382673B (es) | 2025-03-13 |
| US10525104B2 (en) | 2020-01-07 |
| KR102471057B1 (ko) | 2022-11-28 |
| CN107076749B (zh) | 2020-12-29 |
| EP3194974A1 (en) | 2017-07-26 |
| US20170281725A1 (en) | 2017-10-05 |
| KR20170055972A (ko) | 2017-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250905B (en) | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer | |
| IL280521A (en) | Methylated markers for colorectal cancer | |
| IL253756A0 (en) | Biomarker panel for the detection of cancer | |
| DK3240801T3 (da) | Kombinationstumorimmunterapi | |
| SG11201607448PA (en) | Determining cancer agressiveness, prognosis and responsiveness to treatment | |
| HRP20181566T1 (hr) | Biomarkeri raka i njihove uporabe | |
| GB2545361B (en) | Methods of assessing colorectal cancer status | |
| IL251204A0 (en) | Biomarkers and predictive methods | |
| EP3394620C0 (en) | BLADDER CANCER BIOMARKER PROTEINS | |
| IL251903B (en) | Apilimod for use in the treatment of colorectal cancer | |
| EP3690063C0 (en) | DIAGNOSIS OF LUNG CANCER | |
| ZA201802481B (en) | Novel biomarkers and methods of treating cancer | |
| MA43957A (fr) | Biomarqueurs de copanlisib | |
| SG11201606106SA (en) | Specific biomarker set for non-invasive diagnosis of liver cancer | |
| GB201500584D0 (en) | Cancer biomarkers | |
| IL264359A (en) | Combination test for colorectal cancer | |
| GB201413162D0 (en) | Prediction of cancer treatment based on determination of enzymes or metabolites of the kynurenine pathway | |
| MA43958A (fr) | Biomarqueurs copanlisib | |
| HUE040167T2 (hu) | Rákkezelés | |
| DK3250708T3 (da) | Biomarkører for kolorektal cancer-relaterede sygdomme | |
| SG10201913528PA (en) | Methods of diagnosing cancer | |
| IL246558A0 (en) | Novel methods for treating cancer | |
| GB201602210D0 (en) | Detection of cancer | |
| DK3277284T3 (da) | Hidtil ukendte terapier mod kræft | |
| EP3338088A4 (en) | BIOMARKER FOR CORONARY DISEASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |